last
decad
intens
work
relationship
liver
arachidon
acid
cascad
greatli
expand
knowledg
area
research
liver
emerg
major
organ
particip
degrad
elimin
arachidon
product
system
origin
synthesi
liver
arachidon
product
deriv
cyclooxygenas
lipoxygenas
cytochrom
system
pathway
demonstr
particip
ieukotrien
cysteinyileukotrien
mediat
liver
damag
possibl
therapeut
use
prostaglandin
pg
acut
liver
injuri
attract
interest
clinician
articl
review
essenti
featur
regard
role
arachidon
metabolit
liver
diseas
special
focus
cytoprotect
effect
liver
display
pge
synthet
pg
analog
experiment
model
liver
damag
induc
ischemiareperfus
injuri
carbon
tetrachlorid
bacteri
lipopolysaccharid
viral
hepat
possibl
mechan
underli
liver
cytoprotect
experiment
model
therapeut
use
pg
clinic
practic
critic
analyz
basi
avail
evid
patient
fulmin
hepat
failur
primari
graft
nonfunct
follow
liver
transplant
content
abbrevi
alt
alanin
aminotransferas
ast
aspart
aminotransferas
carbon
tetrachlorid
dimethyl
fhf
fulmin
hepat
failur
hbv
hepat
b
viru
il
interleukin
lp
lipopolysaecharid
lt
leukotrien
leukotrien
murin
hepat
pg
prostaglandin
sfhf
subfulmin
hepat
failur
tnf
tumor
necrosi
factor
thromboxan
background
prostaglandin
pg
biolog
activ
polyunsatur
fatti
acid
aris
arachidon
acid
addit
major
role
local
regulatori
factor
mediat
inflamm
pg
shown
uniqu
properti
cytoprotect
cytoprotect
pg
origin
describ
robert
cowork
lancast
robert
robert
et
al
author
observ
pg
abl
protect
gastric
mucosa
varieti
noxiou
stimuli
studi
gave
rise
rapidli
expand
field
research
therapeut
potenti
action
sever
organ
includ
liver
last
decad
much
learn
regard
relationship
liver
compound
arachidon
acid
cascad
pg
leukotrien
lt
normal
patholog
condit
howev
puzzl
far
complet
function
complex
liver
make
understand
relationship
difficult
liver
synthes
virtual
major
product
arachidon
acid
cascad
also
target
biolog
action
liver
hand
major
organ
account
biodegrad
prostanoid
repres
main
rout
elimin
final
metabolit
via
biliari
tree
huber
keppler
moreov
normal
liver
contain
varieti
cell
subpopul
hepatocyt
sever
type
nonparenchym
cell
abl
produc
arachidon
deriv
thu
identif
specif
metabolit
synthes
particular
cell
type
recognit
interact
differ
cell
subpopul
influenc
arachidon
cascad
difficult
still
remain
uncomplet
problem
becom
even
complex
studi
damag
liver
envisag
inflammatori
cell
infiltr
liver
probabl
repres
cellular
subpopul
highest
capac
eicosanoid
synthesi
addit
interact
product
arachidon
cascad
host
messeng
releas
follow
liver
injuri
vasoact
agent
hormon
lymphokin
acut
phase
reactant
other
partial
known
brouwer
et
al
lewi
final
sinc
liver
crucial
biodegrad
elimin
nonhepat
arachidon
deriv
huber
keppler
liver
diseas
influenc
extent
system
arachidon
metabol
huber
et
al
evid
given
specif
compound
case
arachidon
metabolit
may
act
regul
agent
normal
condit
also
mediat
tissu
damag
liver
injuri
add
difficulti
understand
role
particular
eicosanoid
despit
difficulti
experiment
model
use
liver
homogen
isol
liver
cell
isol
perfus
liver
intact
anim
use
establish
basic
concept
regard
relationship
liver
arachidon
deriv
hepatoprotect
liver
synthes
major
metabolit
arachidon
cascad
includ
pg
b
pg
arachidon
deriv
pg
involv
physiolog
process
liver
tabl
c
substanc
act
mediat
liver
damag
due
chemic
ischemia
infect
other
endogen
pg
found
hepatoprotect
condit
liver
damag
modul
extent
immunolog
inflammatori
local
respons
e
exogen
pg
found
benefici
sever
experiment
model
liver
damag
vivo
vitro
f
result
preliminari
clinic
trial
use
pg
therapeut
agent
patient
sever
acut
liver
injuri
encourag
studi
requir
confirm
pg
accept
standard
treatment
form
liver
injuri
furthermor
much
must
still
learn
mechan
pg
behav
hepatoprotect
agent
better
knowledg
intim
mechan
respons
hepatoprotect
improv
therapeut
use
compound
articl
summar
essenti
regard
cytoprotect
effect
pg
liver
mechan
potenti
involv
action
role
compound
clinic
practic
refer
arachidon
acid
deriv
pg
thromboxan
leukotrien
cysteinyilt
forcibl
includ
intim
relationship
pg
relev
role
liver
damag
arachidon
acid
polyunsatur
fatti
acid
integr
phospholipid
plasma
membran
cell
bodi
free
arachidon
acid
releas
membran
store
action
phospholipas
phospholipas
c
activ
specif
stimuli
abnorm
condit
phospholipas
may
activ
unspecif
stimuli
ie
uncontrol
calcium
entri
cell
phospholipas
neg
regul
lipomodulin
glucocorticoidinduc
protein
flower
blackwel
hirata
et
al
lapetina
et
al
l
denni
avail
free
arachidon
acid
rate
limit
step
synthesi
deriv
precursor
convert
biolog
activ
product
three
enzymat
pathway
cyclooxygenas
lipoxygenas
sever
lipoxygenas
act
specif
site
arachidon
acid
system
fig
l
cyclooxygenas
pathway
yield
final
activ
metabolit
classic
pg
pge
pgd
prostacyclin
txa
fig
cyclooxygenas
activ
inhibit
nonsteroid
antiinflammatori
drug
higg
vane
major
lipoxygenas
product
liver
cysteinyllt
lte
deriv
huber
keppler
hagmann
et
al
fig
metabolit
gener
lipoxygenas
act
posit
arachidon
demonstr
produc
cell
present
normal
liver
lipoxygenas
activ
inhibit
fatti
acid
etya
sever
agent
bear
antioxid
activ
nordihydroguayaret
acid
piper
lt
receptorantagonist
specif
inhibitor
lipoxygenas
pathway
develop
fordhutchinson
recent
year
newer
compound
aris
arachidon
acid
action
cytochrom
system
epoxyeicosatrieno
acid
initi
isol
kidney
tissu
capdevila
et
al
found
also
produc
organ
includ
liver
fitzpatrick
murphi
macrophag
ito
cell
also
call
lipocyt
fatstor
cell
typic
fibroblast
myofibroblast
special
contractil
fibroblast
deriv
ito
cell
socal
pit
cell
larg
granular
lymphocyt
locat
insid
hepat
sinusoid
normal
liver
contain
signific
number
polymorphonuclear
leukocyt
lymphocyt
plasma
cell
eosinophil
larg
number
one
cell
type
invad
liver
inflammatori
diseas
organ
le
bail
et
al
cell
abl
synthes
arachidon
acid
deriv
one
metabol
pathway
specif
metabolit
produc
kind
liver
cell
remain
definit
establish
extens
studi
kupffer
cell
endotheli
cell
hepatocyt
kupffer
cell
abl
produc
pg
lt
includ
cysteinyllt
major
arachidon
metabolit
type
cell
pgdz
ltc
brouwer
et
al
sakagami
et
al
basal
condit
kupffer
cell
releas
small
amount
eicosanoid
major
metabolit
kuiper
et
al
stimuli
bacteri
endotoxin
lipopolysaccharid
lp
muramyl
dipeptid
zymosan
iggbear
particl
antigen
challeng
follow
prior
sensit
elicit
mark
increas
synthesi
pg
andor
lt
cell
aderem
et
al
rieder
et
al
releas
kupffer
cell
act
selfmodulatori
signal
cellular
popul
becom
activ
like
direct
indirect
cytoprotect
role
upon
hepatocyt
emphas
kupffer
cell
repres
less
total
liver
cell
account
least
cell
belong
macrophagephagocyt
system
whole
bodi
munthekaa
et
al
fact
reflect
import
role
kupffer
cell
play
clearanc
blood
foreign
ie
endotoxin
bacteria
virus
endogen
ie
circul
tumor
cell
noxiou
materi
anatom
locat
line
hepat
sinusoid
one
side
neighborhood
hepatocyt
plate
function
relev
kupffer
cell
constitut
ultim
barrier
avoid
pathogen
materi
intestin
origin
pass
system
blood
fact
minor
amount
bacteri
endotoxin
usual
present
portal
blood
clear
kupffer
cell
blood
pass
liver
sinusoid
activ
kupffer
cell
result
initi
phagocyt
inflammatori
respons
phagocytosi
accompani
releas
oxygen
free
radic
sever
cytokin
varieti
il
interferon
ifn
gamma
tumor
necrosi
factor
tnf
ct
messeng
releas
mediat
inflammatori
respons
mielivergani
et
al
recent
releas
kupffer
cell
demonstr
busam
et
al
correspond
kupffer
cellderiv
factor
describ
bauer
et
al
turn
mediat
trigger
releas
acut
phase
reactant
protein
larg
hepatocyt
fey
gauldi
also
ito
cell
andu
et
al
activ
kupffer
cell
modifi
usual
quantit
pattern
synthesi
cyclooxygenas
deriv
instead
pgd
becom
predomin
metabolit
releas
trigger
virtual
stimuli
elicit
kupffer
cell
phagocyt
activ
inflammatori
respons
rieder
et
al
b
stimul
lp
induc
mark
sustain
increas
synthesi
cell
karck
et
al
intim
mechan
cyclooxygenas
pathway
shift
toward
synthesi
unsolv
like
involv
calciumand
calmodulindepend
phospholipas
activ
bhatnagar
et
al
appear
requir
na
h
exchang
oper
decker
dieter
intens
releas
import
modul
inflammatori
respons
henc
preserv
integr
liver
sinc
messeng
releas
along
toxic
hepatocyt
may
promot
endotheli
damag
initi
intravascular
coagul
sinusoid
yamada
et
al
fact
endotox
shock
massiv
hepat
necrosi
seen
anim
expos
lp
follow
prior
sensit
inactiv
bacteria
cytokinemedi
see
experiment
liver
injuri
articl
shown
abil
hepatocyt
take
degrad
virtual
nonsatur
tranthi
et
al
thu
sustain
releas
activ
kupffer
cell
might
direct
maintain
local
concentr
level
suffici
exert
neg
feedback
upon
cytokin
releas
kupffer
cell
neg
selfmodul
inhibit
among
function
antigen
express
tumor
cytotox
releas
ili
shirahama
et
al
ifn
coloni
stimul
factor
lpsinduc
releas
inhibit
dosedepend
fashion
karck
et
al
later
case
shown
modul
macrophagederiv
tnf
gene
express
kunkel
et
al
inhibitori
activ
share
even
test
vitro
high
concentr
karck
et
al
unlik
cytokin
lpsinduc
releas
kupffer
cell
inhibit
concentr
virtual
abolish
tnf
product
rim
dexamethason
markedli
inhibit
lpsinduc
product
kupffer
cell
vitro
concentr
glucocorticoid
u
higher
usual
requir
obtain
similar
inhibit
releas
u
busam
et
al
studi
ili
tnft
effect
lp
stimul
releas
kupffer
cell
may
function
relev
regard
autocrin
paracrin
endotheli
cell
synthes
ili
control
kupffer
cell
activ
interest
power
stimulu
releas
infect
kupffer
cell
newcastl
diseas
viru
busam
et
al
immunomodulatori
role
restrict
kupffer
cell
also
includ
action
neutrophil
attenu
local
chang
vascular
permeabl
induc
inflammatori
mediat
suppress
b
cell
cell
prolifer
inhibit
product
ham
et
al
tate
et
al
fanton
et
al
rappaport
dodg
indomethacin
could
expect
inhibitori
action
upon
synthesi
regul
immun
activ
eisenth
quantit
point
view
hepatocyt
pgmetabol
rather
pgsynthes
cell
cell
produc
low
amount
pgi
pge
probabl
act
autocrin
modul
particip
celltocel
commun
contigu
hepatocyt
tranthi
et
al
true
function
relev
pg
hepatocyt
unknown
although
pg
action
upon
plasma
membran
fluiditi
membran
receptor
dave
knacek
glucos
metabol
brass
garriti
et
al
okumura
saito
bile
flow
kaminski
deshpand
describ
bile
salt
increas
synthesi
isol
rat
hepatocyt
wherea
product
reduc
unpublish
data
sinc
suggest
may
decreas
nakatpas
activ
verna
neg
modul
synthesi
bile
salt
uptak
depend
upon
sodium
gradient
across
plasma
membran
may
function
signific
hepatocyt
thought
produc
cyciooxygenas
compound
howev
hepatocyt
also
abl
convert
lta
cysteinyllt
vitro
medina
et
al
chemotact
factor
releas
ethanolstimul
hepatocyt
tent
identifi
ltb
hultcrantz
et
al
suggest
possibl
presenc
lipoxygenas
hepatocyt
result
obtain
laboratori
use
lipoxygenas
inhibitor
suspens
isol
rat
hepatocyt
lend
indirect
support
hypothesi
quiroga
et
al
recent
observ
isol
perfus
rat
liver
sodium
taurochol
physiolog
bile
salt
enhanc
mrna
express
liver
tissu
accompani
rise
hepat
synthesi
cysteinyllt
rodriguezortigosa
et
al
sinc
hepat
cell
bear
bile
salt
receptor
hepatocyt
result
suggest
bile
salt
may
act
enhanc
activ
parenchym
liver
cell
although
altern
explan
definit
exclud
least
two
major
metabolit
arachidon
acid
result
action
system
also
found
produc
hepatocyt
capdevila
et
al
fitzpatrick
murphi
kidney
system
deriv
arachidon
acid
appear
influenc
renal
tubular
na
activ
howev
physiolog
pathophysiolog
relev
compound
liver
still
studi
liver
endotheli
cell
produc
pgi
predomin
metabolit
also
minor
amount
lp
induc
timeand
dosedepend
stimul
prostanoid
synthesi
rieder
et
al
product
relev
sinc
protect
agent
liver
inflamm
pgi
counteract
activ
locallyreleas
substanc
promot
vasoconstrict
platelet
aggreg
leucocyt
adher
needleman
et
al
cysteinyllt
vasoact
agent
alter
inhibit
soon
initi
compromis
liver
microcircul
markedli
amplifi
parenchym
liver
damag
like
endotheli
cell
abl
releas
cysteinyllt
cytokin
particip
network
paracrin
influenc
involv
kupffer
cell
hepatocyt
endotheli
cell
resid
mast
cell
perhap
ito
cell
celltocel
influenc
may
import
modul
immun
inflammatori
respons
lysz
et
al
inde
recent
demonstr
anaphylact
challeng
resid
mast
cell
main
initi
lt
product
liver
hagmann
et
al
recruit
extrahepat
inflammatori
cell
due
local
releas
chemotact
messeng
initi
phase
inflammatori
respons
local
liver
larg
popul
cell
high
abil
eicosanoid
synthesi
thu
liver
inflamm
bulk
eicosanoid
product
account
invad
cell
togeth
kupffer
cell
minor
contribut
remain
cell
type
overproduct
lead
increas
local
concentr
arachidon
acid
deriv
must
born
mind
arachidon
deriv
demonstr
exert
opposit
action
upon
biolog
function
low
high
concentr
rodriguezortigosa
et
al
import
issu
consid
relat
cytoprotect
effect
pg
sinc
pharmacolog
concentr
may
produc
effect
quit
differ
thought
characterist
compound
synthesi
lipoxygenas
deriv
role
liver
diseas
recent
review
huber
keppler
major
function
compound
summar
tabl
relationship
arachidon
acid
deriv
liver
diseas
evalu
varieti
experiment
model
liver
damag
acut
liver
damag
induc
carbon
tetrachlorid
stachura
et
al
guarner
et
al
guarner
et
al
rush
et
al
miba
et
al
dgalactosamin
stachura
et
al
stachura
et
al
gove
et
al
acetaminophen
guarner
et
al
benzvi
et
al
ethanol
stachura
et
al
b
buko
zavodnik
aflatoxin
rush
et
al
tnaphthylisothiocyan
ruwart
et
al
bromobenzen
funkbrentano
et
al
plu
hyperthermia
miyazaki
et
al
normotherm
hypotherm
ischemia
sikujara
et
al
mora
et
al
transient
ischemia
follow
carbon
tetrachlorid
alph
hickman
murin
hepat
abecassi
et
al
lp
endotoxin
alon
associ
either
galactosamin
heat
inactiv
propinebacterium
ach
wendel
et
al
mizoguchi
et
al
observ
total
partial
prevent
one
follow
compound
pge
dimethyl
synthet
analog
prostacyclin
iloprost
synthet
analog
prostacycin
succes
cytoprotect
rather
constant
featur
pg
except
although
partial
effect
ishemia
plu
carbon
tetrachlorid
model
fail
prevent
liver
damag
induc
viru
paracetamol
see
ballet
review
cytoprotect
pg
demonstr
experi
use
intact
anim
isol
perfus
liver
isol
hepatocyt
incub
cultur
point
fact
pg
may
exert
benefici
effect
sever
level
clear
cytoprotect
effect
observ
use
cyclooxygenas
inhibitor
synthas
inhibitor
antagonist
either
dual
cyclooxygenas
lipoxygenas
inhibitor
prevent
least
part
liver
damag
experiment
model
suggest
lt
txa
may
act
mediat
liver
injuri
nagai
et
al
b
hagmann
et
al
hagmann
et
al
tieg
wendel
although
precis
mechan
underli
cytoprotect
effect
pg
acut
liver
injuri
remain
precis
defin
suggest
obtain
experiment
studi
use
best
character
model
acut
liver
damag
sinc
liver
transplant
becom
mainstay
therapi
irrevers
acut
chronic
liver
diseas
mechan
liver
damag
induc
hypoxia
reperfus
focu
major
attent
hepatologist
ischemiareperfus
liver
injuri
main
mechan
respons
occurr
primari
graft
nonfunct
complic
lead
patient
death
retransplant
undertaken
although
mechan
liver
damag
induc
ischemiareperfus
injuri
need
clarifi
believ
reentri
blood
liver
graft
overproduct
toxic
oxygen
radic
follow
endotheli
cell
damag
kupffer
cell
activ
occur
caus
disturb
liver
microcircul
widespread
alter
oxygen
organ
secondari
parenchym
damag
ensu
caldwellkenkel
et
al
goto
oxid
stress
thought
key
event
product
tissu
damag
follow
ischemiareperfus
mccord
koo
et
al
demonstr
occurr
delay
nonreflow
phenomenon
minut
reperfus
crucial
compromis
microcircul
type
hepat
injuri
sever
nonreflow
phenomenon
secondari
liver
damag
markedli
attenu
rat
pretreat
hr
ischemia
longact
form
superoxid
dismutas
thu
demonstr
superoxid
anion
mediat
least
part
occlus
liver
microcircul
koo
et
al
therefor
ischemiareperfus
liver
injuri
follow
kupffer
cell
activ
endotheli
cell
rather
hepatocyt
like
primari
target
oxid
stress
plug
capillari
neutrophil
lead
derang
microcircul
henc
parenchym
liver
damag
takei
et
al
sever
relationship
arachidon
deriv
ischemiareperfus
liver
injuri
report
includ
benefici
effect
exogen
pg
suggest
chemokinet
factor
releas
reperfus
might
eicosanoid
naqpal
et
al
probabl
ltb
hepat
synthesi
arachidon
acid
deriv
modifi
result
ischemiareperfus
liver
injuri
isol
kupffer
cell
warm
hypoxiareoxygen
induc
chang
pg
synthesi
markedli
increas
product
combi
et
al
contrast
reoxygen
follow
hr
cold
hypoxia
reduc
releas
prostacyclin
kupffer
cell
respect
wherea
synthesi
txa
iipoxygenas
deriv
unchang
tnft
releas
kupffer
cell
increas
warm
cold
ischemiareoxygen
experi
combi
et
al
thu
case
pgslt
ratio
ratio
reduc
face
increas
tnf
level
fall
ratio
may
role
promot
local
adhes
leucocyt
platelet
aggreg
well
known
vasoconstrict
platelet
aggreg
induc
effici
counteract
endotheli
provid
endotheli
integr
preserv
howev
ischemiareperfus
liver
injuri
endotheli
cell
damag
earli
follow
reperfus
sutto
et
al
thu
decreas
ratio
endotheli
environ
may
pathogen
import
reinforc
concept
lower
ratio
also
observ
rat
liver
follow
min
warm
ischemia
bess
et
al
studi
imidazol
inhibitor
significantli
improv
surviv
anim
amelior
rat
receiv
imidazol
stabl
analog
iloprost
bess
et
al
therefor
abrog
txa
overproduct
togeth
suppli
activ
favor
modifi
outcom
transplant
anim
relev
predomin
influenc
activ
highlight
studi
treatment
indomethacin
plu
iloprost
ad
solut
flush
graft
infus
iv
recipi
anim
markedli
improv
earli
surviv
liver
transplant
pig
seelo
et
al
anim
indomethacin
fulli
inhibit
synthesi
pg
effect
analog
predomin
hand
improv
function
liver
graft
transplant
pig
hr
cold
ischemia
mora
et
al
isol
perfus
cat
liver
subject
hypoxia
araki
lefer
vasoconstrict
tissu
edema
also
compromis
tissu
oxygen
increas
liver
damag
ischemiareperfus
injuri
addit
increas
damag
potenti
condit
tissu
hypoxia
fact
isol
rat
hepatocyt
preincub
hr
hypoxia
kill
addit
ltca
detriment
effect
hepatocyt
preincub
normoxia
trudel
et
al
ltcainduc
death
hypox
cell
might
relat
activ
calcium
ionophor
serhan
et
al
studi
surviv
hypox
hepatocyt
reduc
calcium
ionophor
kill
cell
normox
hepatocyt
thu
hypox
cell
defici
overcom
alter
calcium
flux
way
calcium
channel
blocker
verapamil
benefici
effect
surviv
pig
liver
graft
transplant
hr
cold
preserv
mora
et
al
reinforc
potenti
calcium
channel
blocker
hepatoprotect
agent
deakin
et
al
inflammatori
respons
kupffer
cell
like
amplifi
synthesi
reduc
suggest
data
combi
et
al
previous
note
releas
kupffer
cell
selfmodul
intens
inflammatori
respons
thu
low
product
pge
might
associ
increas
releas
tnft
cytokin
contribut
widespread
tissu
damag
massiv
hepat
necrosi
constitut
end
result
sever
ischemiareperfus
liver
injuri
therefor
hepatoprotect
point
view
effort
direct
protect
parenchym
liver
cell
mainli
prevent
earliest
possibl
step
damag
endotheli
cell
recent
report
bile
duct
epitheli
cell
less
vulner
hepatocyt
hypoxia
howev
sensit
reoxygenationinduc
damag
noack
et
al
whether
hitherto
unrecogn
reoxygenationinduc
damag
may
contribut
earli
graft
malfunct
investig
carbon
tetrachlorid
toxic
compound
wide
use
experiment
model
acut
liver
injuri
also
chronic
administr
induc
liver
cirrhosi
stachura
et
al
report
first
time
hepatoprotect
effect
liver
damag
mgkg
sc
nontreat
rat
produc
fatti
degener
hr
toxic
challeng
sever
centrilobular
necrosi
hr
later
togeth
mark
increas
serum
aminotransferas
rat
treat
gkg
min
hr
cci
administr
show
fatti
degener
necrosi
absent
increas
serum
aminotransferas
transient
time
lower
control
rat
ultrastructur
promin
prolifer
balloon
endoplasm
reticulum
seen
control
rat
wherea
abnorm
observ
rat
convert
liver
system
trichloromethyl
radic
highli
reactiv
speci
caus
lipid
peroxid
polyunsatur
fatti
acid
cell
membran
lead
membran
disrupt
cell
death
farber
stachura
et
al
hypothes
hepatoprotect
mechan
model
stabil
membran
endoplasm
reticulum
subsequ
studi
confirm
cytoprotect
action
liver
damag
ruwart
et
al
rule
interfer
eel
absorpt
metabol
scaveng
trichloromethyl
radic
signific
mechan
underlay
cytoprotect
rush
et
al
studi
perform
laboratori
show
similar
protect
liver
toxin
demonstr
properti
share
pgi
lipid
peroxid
evalu
malondialdehyd
gener
demonstr
occur
upon
exposur
isol
hepatocyt
addit
studi
provid
initi
insight
regard
involv
lipoxygenas
deriv
mediat
liver
damag
sinc
dual
cyclooxygenas
lipoxygenas
inhibitor
protect
isol
rat
hepatocyt
injuri
wherea
indomethacin
guarner
et
al
guarner
et
al
indomethacin
increas
damag
isol
rat
hepatocyt
ad
cell
suspens
earli
toxin
preincub
liver
cell
lowdos
ethanol
effect
stimul
pg
synthesi
attenu
toxic
effect
suggest
endogen
pg
might
afford
protect
guarner
et
al
calcium
depend
hepatotox
demonstr
cultur
hepatocyt
casini
farber
propos
calciumdepend
activ
membran
phospholipas
take
place
ccl
exposur
lamb
schwertz
uncontrol
membran
phospholipas
activ
caus
structur
degrad
membran
system
cell
lead
cellular
breakdown
phospholipas
activ
inhibit
high
intracellular
level
camp
lapetina
et
al
sinc
stimul
adenyl
cyclas
bind
plasma
membran
receptor
samuelsson
et
al
believ
phospholipas
inhibit
would
mechan
underlay
pg
hepatoprotect
although
calcium
entri
hepatocyt
may
earli
event
toxic
liver
injuri
lauterburg
secondari
gener
activ
phospholipas
like
repres
near
final
step
irrevers
cell
damag
common
hepatotoxin
affect
cell
membran
system
schann
et
al
thu
prevent
phospholipas
activ
may
attenu
secondari
damag
mechan
influenc
oxid
stress
due
trichloromethyl
radic
sinc
lipid
peroxid
demonstr
occur
follow
cci
poison
two
point
need
consid
lipid
peroxid
lead
function
chang
structur
damag
cell
membran
system
becom
appar
b
must
rememb
oxid
stress
caus
lipid
peroxid
also
affect
nonlipid
cellular
target
protein
dna
carbohydr
tribbl
et
al
fact
oxid
hepatocellular
injuri
due
inactiv
specif
membran
transport
protein
plasma
membran
endoplasm
reticular
ca
atpas
associ
inabl
mitochondria
retain
calcium
lead
increas
cytosol
free
calcium
bellomo
et
al
thought
sustain
increas
cytosol
calcium
result
disrupt
cytoskelet
element
activ
phospholipas
proteas
lead
cell
death
tribbl
et
al
first
point
relat
fact
lipid
peroxid
increas
microviscos
reduct
fluiditi
cell
membran
ohyashiki
et
al
chang
microenviron
cell
membran
milieu
markedli
modifi
function
membraneassoci
system
activ
na
atpas
adenyl
cyclas
membranebound
enzym
number
mobil
membran
carrier
schachter
number
hepatotox
agent
believ
alter
hepatocyt
function
increas
membran
microviscos
ie
monohydroxi
bile
acid
steroid
chlorpromazin
compound
tertbutyl
hydroperoxid
caus
cell
damag
death
causal
relat
abil
produc
lipid
peroxid
use
studi
evalu
alter
schnellmann
recent
studi
masaki
et
al
shown
addit
pge
protect
liver
injuri
induc
dgalactosamin
author
use
tertbutyl
hydroperoxid
evalu
effect
pge
lipid
peroxidationdepend
kill
isol
rat
hepatocyt
cultur
pget
significantli
reduc
cell
kill
despit
inabl
prevent
lipid
peroxid
evalu
malondialdehyd
gener
sinc
pg
increas
camp
activ
adenyl
cyclas
samuelsson
et
al
camp
thought
stabil
plasma
membran
effect
dibutyryl
camp
tertbutyl
hydroperoxidedepend
cell
kill
test
compound
neither
inhibit
lipid
peroxid
reduc
cell
death
thu
rule
camp
mediat
hepatoprotect
exert
pg
model
serial
measur
plasma
membran
microviscos
hepatocyt
incub
tertbutyl
hydroperoxid
demonstr
progress
timedepend
increas
membran
microviscos
reflect
effect
lipid
peroxid
physicochem
characterist
plasma
membran
howev
addit
either
pgei
simultan
peroxid
agent
result
decreas
membran
microviscos
despit
ongo
lipid
peroxid
masaki
et
al
find
may
explain
least
part
unspecif
cytoprotect
effect
pg
sinc
agent
damag
liver
increas
cell
membran
microviscos
primari
secondari
event
properti
share
knazek
et
al
dave
knazek
thu
provid
common
mechan
three
character
cytoprotect
pg
may
protect
liver
varieti
toxic
agent
sever
experiment
model
liver
injuri
base
inject
bacteri
endotoxin
lp
repres
model
relat
role
arachidon
deriv
pg
cytoprotect
summar
lp
stimul
cell
macrophagephagocyt
system
produc
sever
inflamatori
mediat
lt
sever
cytokin
small
amount
lp
inject
normal
anim
littl
liver
cell
necrosi
seen
howev
model
acut
revers
cholestasi
occur
lp
inject
pathogenesi
form
cholestasi
clinic
repres
cholestasi
associ
sepsi
sever
infect
acut
sever
inflammatori
diseas
unknown
quiroga
attribut
least
part
excess
product
cysteinyllt
keppler
et
al
sinc
inject
high
dose
ltc
guinea
pig
induc
cholestasi
also
develop
simultan
administr
pharmacolog
dose
pge
rat
keppler
et
al
cholestat
effect
high
dose
confirm
isol
perfus
rat
liver
rodriguezortigosa
et
al
ltc
induc
signific
decreas
biliari
bile
salt
output
bile
flow
hand
white
et
al
observ
tnft
major
mediat
endotoxin
action
markedli
inhibit
uptak
taurochol
cultur
hepatocyt
intact
anim
endotoxin
inject
mgkg
decreas
basal
bile
flow
bilesalt
stimul
bile
flow
treatment
anim
monoclon
antitnf
antibodi
endotoxin
inject
prevent
develop
cholestasi
white
et
al
recent
author
shown
produc
inhibitori
effect
doseand
timedepend
fashion
neither
tnfct
endotoxin
ad
cultur
media
treat
hepatocyt
abl
augment
inhibit
induc
concentr
uml
inhibit
bile
salt
uptak
compar
serum
level
cytokin
observ
acut
inflamm
green
et
al
result
repres
insight
mechan
endotoxininduc
cholestasi
use
lipoxygenas
inhibitor
lt
antagonist
anticytokin
antibodi
avala
agent
block
inflammatori
respons
endotoxin
might
therapeut
interest
endotoxin
caus
dosedepend
activ
kupffer
cell
promot
inflammatori
respons
intens
abl
kill
liver
cell
induc
endotox
shock
intravascular
coagul
mizoguchi
et
al
interest
experiment
model
endotoxininduc
liver
injuri
experiment
anim
sensit
day
endotoxin
challeng
iv
inject
kill
bacteria
corynebacterium
parvum
laetobacillu
casei
p
acn
tsutsui
et
al
hashimoto
et
al
anim
iv
inject
lp
dose
littl
effect
nonpresensit
anim
induc
massiv
liver
necrosi
iv
inject
mice
heatkil
p
ach
gramposit
anaerob
follow
week
later
small
amount
lp
given
iv
caus
within
hr
massiv
hepat
necrosi
death
major
anim
mizoguchi
et
al
studi
hepat
necrosi
attribut
proteinlik
hepatocytotox
factor
releas
liver
macrophag
mizoguchi
et
al
compar
control
anim
mice
given
pge
gkg
simultan
lp
show
dramat
reduct
liver
damag
hr
lp
inject
compar
control
anim
pgei
reduc
mice
mortal
lower
alanin
amino
transferas
releas
liver
stain
show
widespread
parenchym
necrosi
control
mice
liver
cell
necrosi
lobular
permeat
macrophag
lymphocyt
plasma
cell
observ
pgetreat
anim
although
intim
mechan
underli
hepatoprotect
effect
obscur
least
two
action
pge
appear
particip
author
demonstr
cytotox
isol
hepatocyt
mediat
cultur
supernat
lpsstimul
liver
adher
cell
prepar
mice
inject
p
ach
virtual
inhibit
addit
pgei
hepatocyt
suspens
evalu
trypan
blue
exclus
protein
synthesi
target
hepatocyt
mizoguchi
et
al
furthermor
addit
pge
togeth
lp
adher
cell
cultur
result
mark
loss
cytotox
abil
cultur
supernat
test
hepatocyt
suspens
data
seem
indic
pgei
inhibit
releas
cytotox
factor
activ
adher
cell
also
protect
hepatocyt
damag
effect
factor
lp
well
known
stimulu
releas
solubl
cytotox
activ
kupffer
cell
karck
et
al
hepatocytotox
factor
report
mizoguchi
et
al
might
correspond
one
substanc
sinc
lp
induc
kupffer
cell
releas
sever
mediat
includ
cytokin
ill
tnf
ifngamma
superoxid
radic
lt
pg
mainli
pgez
previous
note
see
section
selfmodulatori
effect
upon
kupffer
cell
inhibit
releas
cytokin
exclud
busam
et
al
thu
attenu
lpsinduc
cytokin
releas
kupffer
cell
appear
congruent
mechan
pge
hepatoprotect
model
fact
mahl
et
al
show
exogen
pge
inhibit
tnfct
product
kupffer
cell
prevent
endotoxininduc
mortal
mice
experiment
model
increas
liver
content
pg
lt
biliari
output
cysteinyllt
preced
hepat
necrosi
signal
activ
major
branch
arachidon
cascad
kawada
et
al
addit
hepatoprotect
role
potenti
damag
role
txa
must
also
note
hepat
necrosi
induc
inject
lp
c
parvumtr
mice
prevent
select
txa
synthas
inhibitor
mgkg
also
receptor
antagonist
mgkg
anim
attenu
liver
necrosi
nagai
et
al
agreement
protect
abil
pg
cellular
damag
horton
wood
dgalactosamin
caus
minor
hepat
damag
associ
inject
lp
determin
occurr
fulmin
hepat
mice
demonstr
mediat
lymphoreticular
cell
chojkier
fierer
addit
studi
identifi
subset
cell
involv
mechan
lead
liver
damag
mice
treat
ogalactosamin
inject
lpsactiv
autolog
spleen
cell
produc
sever
hepat
necrosi
shiratori
et
al
studi
lpsactiv
spleen
cell
place
dish
subpopul
adher
cell
rich
activ
macrophag
recov
inject
ogalactosaminetr
mice
result
mark
augment
liver
necrosi
coupl
increas
releas
oxygen
free
radic
malondialdehyd
gener
pretreat
adher
cell
inject
mice
lipoxygenas
inhibitor
azelastin
calcium
channel
blocker
verapamil
result
complet
abrog
free
radic
gener
mark
attenu
liver
damag
less
effect
pretreat
adher
cell
lipoxygenas
inhibitor
ketotifen
shiratori
et
al
addit
ltddlte
receptor
antagonist
prevent
dgalactosamin
plu
endotoxininduc
fulmin
hepat
keppler
et
al
wherea
exogen
associ
ogalactosamin
caus
morpholog
similar
fulmin
hepat
tieg
wendel
suspect
vasoconstrict
lead
liver
hypoxia
subsequ
reperfus
injuri
may
underli
mechan
iwai
jungermann
singlestrand
rna
viru
coronaviru
famili
produc
straindepend
spectrum
liver
diseas
inbr
strain
mice
mice
strain
fulli
resist
wherea
balbcj
mice
fulli
suscept
acut
infect
die
fulmin
hepat
direct
cytopath
effect
immunolog
factor
particip
liver
damag
abecassi
et
al
fulli
suscept
mice
infect
determin
increas
serum
aminotransferas
begin
hr
inoculu
continu
rise
death
anim
occur
averag
hr
inocul
mice
treat
singl
dose
dmpgez
ip
given
either
min
hr
hr
inocul
show
elev
aminotransferas
howev
protect
seen
rat
treat
hr
inocul
confluent
liver
necrosi
nontreat
mice
parenchym
necrot
foci
given
observ
hr
infect
howev
mice
surviv
unchang
mice
treat
neither
cytoprotect
effect
chang
surviv
could
observ
signific
cytoprotect
dmpge
observ
hepatocyt
cultur
infect
manifest
mark
reduct
sincyti
transform
hepatocyt
monolay
cell
death
macrophag
procoagul
activ
demonstr
nontreat
mice
undetect
treat
anim
abecassi
et
al
lack
effect
mice
surviv
attribut
extrahepat
viral
replic
tissu
damag
includ
brain
cytoprotect
liver
damag
probabl
includ
sever
mechan
abrog
macrophag
procoagul
activ
suggest
secondari
damag
due
intravascular
coagul
prevent
sinc
macrophag
procoagul
activ
depend
releas
cytokin
result
macrophag
activ
attenu
macrophag
cytotox
activ
could
contribut
cytoprotect
treat
mice
direct
damag
induc
cultur
hepatocyt
impli
cytophat
effect
cytoprotect
activ
vitro
model
may
due
either
antivir
activ
reduct
cell
sensit
cytopath
effect
rat
hepat
induc
frog
viru
associ
enhanc
product
cysteinyllt
hagmann
et
al
treatment
lipoxygenas
inhibitor
induc
reduct
serum
aminotransferas
level
suggest
cysteinyllt
relev
mediat
liver
damag
model
mechan
ethanolinduc
liver
damag
still
partial
unknown
rat
fed
satur
fat
develop
alcohol
liver
damag
rat
fed
corn
oil
ethanol
develop
fatti
degener
necrosi
inflamm
fibrosi
liver
nanji
et
al
b
author
measur
sever
potenti
mediat
liver
injuri
one
month
plasma
supernat
suspens
nonparenchym
liver
cell
mainli
kupffer
cell
rat
fed
alcohol
either
satur
fat
corn
oil
main
find
progress
rise
level
plasma
endotoxin
level
plasma
kuppffer
cell
supernat
stabl
metabolit
txa
observ
corn
oil
fed
rat
addit
rat
show
tendenc
toward
increas
plasma
wherea
rat
fed
satur
fat
show
higher
level
corn
oil
fed
rat
histopatholog
sever
liver
diseas
directli
correl
plasma
level
endotoxin
txb
invers
nanji
b
although
preliminari
data
appear
reinforc
relev
damag
agent
mechan
endotoxin
level
increas
rat
fed
corn
oil
causal
relationship
sever
liver
diseas
import
point
investig
b
potenti
relev
mechan
may
improv
liver
damag
irrespect
caus
abil
pg
stimul
liver
regener
mcneil
et
al
shown
synthesi
kupffer
cell
sharpli
increas
hour
follow
partial
hepatectomi
appar
preced
onset
dna
synthesi
calleri
et
al
liver
regener
hepat
mass
return
origin
valu
overproduct
pge
kupffer
cell
subsid
slowli
suggest
pge
may
factor
modul
rate
hepat
regener
although
relationship
chang
product
kupffer
cell
liver
regen
activ
might
mere
coincident
addit
data
suggest
causal
relationship
stimul
mitogenesi
hepatocyt
miura
fukui
andrei
et
al
increas
homogen
regener
liver
macmanu
braceland
cirrhot
rat
treat
underw
partial
hepatectomi
mitot
index
hr
procedur
significantli
higher
nontreat
rat
indomethacin
given
hr
hepatectomi
induc
fall
mitot
index
control
valu
partial
restor
administr
urakawa
et
al
neg
influenc
cyclooxygenas
inhibitor
block
synthesi
upon
rate
hepat
regener
report
author
macmanu
braceland
kwon
et
al
addit
well
known
pg
increas
intracellular
camp
level
camp
intracellular
signal
cell
prolifer
pastan
et
al
thu
enhanc
regener
rate
liver
may
add
initi
cytoprotect
minim
deterior
liver
function
follow
liver
injuri
c
anoth
potenti
benefici
effect
pg
liver
injuri
sporad
report
possibl
antifibrogen
activ
administr
delay
collagen
format
deposit
liver
rat
subject
cholinedefici
diet
induc
liver
damag
ruwart
et
al
hand
reduct
marker
liver
cirrhosi
rat
receiv
cci
chronic
basi
observ
group
anim
treat
dual
cycloxygenas
lipoxygenas
inhibitor
mourel
et
al
relev
find
long
term
evolut
chronic
liver
diseas
still
unknown
evid
benefici
effect
varieti
pg
experiment
acut
liver
damag
justifi
use
treatment
fulmin
fhf
subfulmin
hepat
failur
sfhf
fhf
sfhf
defin
respect
develop
hepat
encephalopathi
within
week
week
month
initi
jaundic
result
acut
liver
injuri
hepat
virus
b
c
e
drug
ie
paracetamol
isoniazid
halothan
toxin
ie
amanitotoxin
varieti
miscellan
condit
wilson
diseas
acut
fatti
liver
pregnanc
liver
ischemia
commonest
caus
fhf
sfhf
schalm
et
al
fhf
carri
bad
prognosi
mortal
rate
rang
seri
patient
publish
liver
transplant
era
de
knegt
schalm
specif
treatment
avail
condit
exclud
case
due
paracetamol
overdos
nacetylcystein
provid
substrat
glutathion
synthesi
prescott
et
al
amanita
phalloid
poison
penicillin
g
silirimarin
inhibit
uptak
amanitotoxin
hepatocyt
sinclair
et
al
publish
first
studi
use
pg
fhf
author
report
consecut
patient
fhf
sfhf
attribut
acut
hepat
due
hepat
viru
hav
case
hepat
b
viru
hbv
case
nona
nonb
type
nanb
case
receiv
intraven
pgei
infus
initi
dose
subsequ
increas
gkghr
therapi
maintain
day
oral
start
dose
rang
mgday
patient
liver
function
test
deterior
pge
withdraw
drug
restart
five
patient
die
three
cerebr
edema
two
liver
transplant
grade
iii
iv
hepat
encephalopathi
present
remain
patient
surviv
without
need
liver
transplant
survivor
show
grade
ii
hepat
encephalopathi
present
progress
grade
iii
iv
observ
two
case
pge
start
relaps
observ
withdraw
pge
three
patient
fhf
attribut
nanb
hepat
respond
well
one
pgei
cours
variabl
durat
clinic
cours
three
patient
repres
fig
mechan
underli
benefici
effect
pget
fhf
uncertain
author
studi
includ
antivir
immunosuppress
metabol
activ
possibl
mechan
surviv
rate
fhf
patient
medic
therapi
obtain
seri
impress
figur
howev
studi
unblind
uncontrol
thiel
comment
result
sinclair
et
al
rememb
initi
studi
fhf
patient
use
corticosteroid
exchang
transfus
hyperbar
oxygen
coenzym
infus
crosscircul
human
be
anim
charcoal
hemoperfus
also
yield
impress
surviv
rate
compar
histor
control
howev
none
treatment
surviv
first
random
control
trial
thu
caution
need
consid
otherwis
potenti
lifesav
therapi
patient
fhf
sfhf
thu
bernuau
et
al
report
patient
treat
intraven
pge
recov
fhf
due
hbv
hepat
without
need
liver
transplant
surviv
rate
similar
observ
group
period
patient
hbvinduc
fhf
inde
three
transplantfre
survivor
studi
hepat
encephalopathi
suggest
sever
acut
hepat
rather
true
fhf
bernuau
et
al
author
bernuau
et
al
report
anoth
seri
patient
fhf
due
drug
patient
undetermin
etiolog
patient
given
pge
gkghr
recoveri
emerg
liver
transplant
death
parallel
find
hbv
patient
patient
recov
medic
treatment
alon
belong
subgroup
patient
exhibit
encephalopathi
admiss
sharp
contrast
result
bernuau
et
al
b
obrien
et
al
recent
report
patient
either
viral
hav
hbv
toxic
paracetamol
paracetamol
plu
alcohol
carbamazepin
sodium
diclofenac
fhf
receiv
intraven
pgei
ghr
averag
day
ten
patient
grade
iii
iv
hepat
encephalopathi
patient
grade
ii
sixteen
patient
surviv
without
need
liver
transplant
author
identifi
small
liver
volum
less
cc
measur
ct
scan
signific
predictor
death
need
transplant
wherea
interv
onset
diseas
initi
treatment
less
day
predict
full
recoveri
medic
treatment
obrien
et
al
author
obrien
et
al
independ
report
seri
patient
paracetamolinduc
acut
hepat
failur
four
patient
grade
iii
iv
hepat
encephalopathi
grade
ii
remain
seven
patient
refer
liver
transplant
present
admiss
alanin
aminotransferas
aspart
aminotransferas
ast
valu
iuml
respect
mean
bilirubin
level
exceed
ml
mean
prothrombin
time
prolong
twice
control
valu
two
patient
receiv
nacetylcystein
within
hr
ingest
paracetamol
drug
minim
paracetamol
hepatotox
given
within
period
time
also
present
sever
hepat
failur
must
consid
characterist
admiss
patient
paracetamol
overdos
report
associ
mortal
rate
greater
patient
studi
obrien
et
al
receiv
intraven
pge
ghr
start
day
paracetamol
intak
pge
maintain
averag
day
patient
surviv
without
need
liver
transplant
inde
patient
requir
dialysi
renal
failur
common
complic
paracetamolinduc
fhf
differ
effect
pge
fhf
describ
see
tabl
might
explain
differ
one
follow
point
criteria
inclus
patient
trial
criteria
defin
grade
hepat
encephalopathi
requir
indic
liver
transplant
altern
true
differ
sever
ill
therapi
initi
dose
pge
similar
studi
support
care
given
patient
assum
correct
sinc
studi
perform
liver
unit
experienc
manag
patient
fhf
therefor
blind
control
studi
requir
establish
true
efficaci
pge
fhf
obtain
predict
paramet
allow
earlier
indic
liver
transplant
high
risk
nonrespons
medic
therapi
alon
recent
first
random
control
trial
evalu
effect
pg
fhf
report
abstract
form
sheener
et
al
unfortun
trial
stop
year
patient
enrol
previous
calcul
requir
patient
obtain
statist
signific
decreas
mortal
patient
thu
data
trial
limit
valu
found
patient
given
ghr
iv
surviv
wherea
control
group
survivor
surviv
wors
viral
placebo
drugor
toxicinduc
hepat
placebo
encourag
data
patient
given
within
day
onset
symptom
surviv
recent
result
emphas
need
extens
trial
valid
use
pg
fhf
previous
note
primari
graft
nonfunct
remain
major
sourc
morbid
mortal
patient
undergo
liver
transplant
quiroga
et
al
primari
graft
nonfunct
unspecif
term
clarifi
precis
etiolog
graft
failur
thought
ischemia
reperfus
graft
injuri
main
mechan
case
rule
earli
graft
failur
diagnos
within
hr
follow
oper
characterist
manifest
primari
graft
nonfunct
includ
failur
graft
make
bile
high
rapidli
rise
level
serum
aminotransferas
sever
coagulopathi
requir
repeat
administr
blood
product
patient
show
postop
recoveri
conscious
requir
mainten
mechan
ventil
invari
hepat
encephalopathi
coma
ensu
frequent
catastroph
pictur
compound
continu
bleed
surgic
bed
renal
failur
hemodynam
instabl
set
altern
death
liver
retransplant
offer
patient
surviv
rate
minim
attrit
occur
thereaft
greig
et
al
report
benefici
effect
iv
infus
pgei
outcom
patient
primari
graft
nonfunct
first
report
includ
patient
select
octob
juli
three
patient
show
ast
level
plateau
ul
first
three
day
postop
sever
coagulopathi
product
low
amount
poor
qualiti
bile
ten
patient
rapidli
rise
ast
ul
scant
bile
product
mark
coagulopathi
primari
graft
nonfunct
diagnos
five
patient
list
retransplant
nontreat
group
eight
patient
treat
group
start
pge
infus
initi
subsequ
increas
maximum
ghr
achiev
side
effect
occur
three
patient
nontreat
group
retranspl
within
hr
initi
transplant
two
surviv
wherea
organ
avail
remain
two
patient
die
respect
day
transplant
surviv
rate
nontreat
group
seven
eight
patient
receiv
pge
day
treatment
recov
aliv
month
posttranspl
surviv
rate
patient
die
group
receiv
pge
less
hr
retranspl
eventu
die
first
glanc
result
brilliant
seem
demonstr
pgei
effect
therapi
primari
graft
nonfunct
howev
preliminari
studi
limit
author
state
although
data
intrigu
one
unequivoc
conclud
role
pgei
treatment
primari
graft
nonfunct
random
control
trial
must
undertaken
number
patient
includ
studi
spars
ast
level
time
diagnosi
primari
graft
nonfunct
nonsignificantli
differ
group
howev
one
five
nontreat
patient
show
ast
valu
ul
two
eight
pgetreat
patient
ast
valu
limit
rise
ast
level
express
ul
x
hr
significantli
higher
nontreat
pgettreat
patient
primari
graft
nonfunct
diagnos
significantli
earlier
nontreat
patient
hr
admit
intens
care
unit
follow
oper
receiv
pge
hr
differ
might
suggest
nontreat
patient
deterior
faster
greater
extent
treatedon
clot
test
deterior
similar
extent
group
limit
valu
sinc
one
assum
patient
receiv
substitut
therapi
fresh
frozen
plasma
cryoprecipit
intraop
requir
blood
blood
product
oper
time
well
recogn
paramet
influenc
graft
patient
surviv
given
studi
final
import
clinic
paramet
could
contribut
better
knowledg
statu
patient
given
paper
despit
limit
result
obtain
pge
infus
remark
deserv
comment
twelv
hour
pge
start
seven
treat
patient
exclud
patient
retranspl
exhibit
drop
ast
valu
rang
ul
x
hr
mean
decreas
ast
ul
even
impress
chang
clot
factor
factor
v
chang
factor
vii
improv
prothrombin
time
sec
sec
partial
thromboplastin
time
sec
sec
dramat
unlik
improv
seven
patient
occur
hr
follow
onset
pge
infus
relat
pge
treatment
appear
two
effect
one
hand
reduc
hepatocellular
necrosi
improv
liver
function
extent
virtual
normal
clot
test
observ
suggest
least
transitorili
initi
microcirculatori
alter
respons
hepatocellular
damag
revers
greig
et
al
consid
mechan
like
respons
primari
graft
nonfunct
transplant
patient
includ
studi
ischemiareperfus
damag
primari
target
kind
injuri
liver
sinusoid
cell
sensit
hepatocyt
hypoxia
oxid
damag
author
studi
hypothes
vasodil
induc
pge
may
account
part
benefici
effect
howev
pg
e
seri
also
acceler
liver
regener
tissu
repair
effect
relev
treatment
primari
graft
nonfunct
skouteri
et
al
accord
experiment
data
factor
critic
success
therapeut
intervent
ischemiareperfus
liver
injuri
time
initi
pg
infus
thu
seem
reason
presenc
sign
poor
graft
function
graft
reperfus
absenc
bile
format
progress
hemostat
deterior
pge
cytoprotect
compound
start
intraop
sinc
endotheli
adher
leukocyt
platelet
appear
one
earlier
step
lead
irrevers
liver
damag
earli
use
graft
reperfus
compound
antiaggregatori
vasodilatori
properti
seem
advic
drug
stimul
prostacyclin
gener
ferrero
et
al
prostacyclin
mora
et
al
analog
iloprost
bess
et
al
prove
use
experiment
model
ischemiareperfus
liver
injuri
earli
administr
compound
either
alon
combin
pg
olthoff
et
al
antioxid
drug
mccord
might
minim
graft
injuri
due
ischemiareperfus
far
know
pg
test
prevent
acut
reject
liver
transplant
patient
pgei
analog
misoprostol
g
qid
po
week
recent
report
significantli
reduc
incid
acut
reject
compar
placebo
vs
patient
p
renal
transplant
recipi
immunosuppress
cyciosporin
prednison
moran
well
known
pg
e
seri
exhibit
immunosuppress
properti
howev
misoprostol
lack
immunosuppress
activ
dose
use
studi
goodwin
clay
synergi
eicosanoid
immunosuppress
demonstr
thu
addit
misoprostol
cyclosporin
prednison
could
respons
reduct
renal
allograft
reject
observ
moran
et
al
experiment
cardiac
transplant
misoprostol
found
reduc
need
cyclosporin
improv
graft
surviv
wiederkehr
et
al
therefor
possibl
contribut
misoprostol
prevent
acut
reject
liver
transplant
recipi
rule
effect
treatment
chronic
activ
hepat
due
hcv
hbv
infect
success
treatment
hbv
chronic
activ
hepat
achiev
patient
receiv
drug
hoofnagl
thoma
therapeut
efficaci
patient
chronic
hbv
infect
depend
upon
induct
immun
respons
vigor
enough
elimin
infect
hepatocyt
inhibit
hbv
replic
camp
et
al
import
part
immun
respons
hbv
enhanc
synthesi
seri
natur
occur
antivir
protein
synthetas
peter
sinc
defect
immun
respons
underli
chronif
hbv
infect
immunosuppress
activ
seem
desir
time
hbv
elimin
recent
shown
cultur
liver
biopsi
patient
hbv
chronic
activ
hepat
addit
ifnt
markedli
stimul
pge
synthesi
andreon
et
al
previous
note
well
known
immunosuppress
properti
author
hypothes
augment
synthesi
pge
result
ifnct
administr
could
neg
effect
regard
hbv
clearanc
hand
inhibit
pg
synthesi
shown
increas
endogen
releas
synthetas
product
andreon
et
al
preliminari
clinic
studi
nine
hbsagposit
patient
chronic
activ
hepat
given
ifng
mu
sc
either
alon
pretreat
indomethacin
mg
po
compar
pretreat
pretreat
indomethacin
associ
significantli
higher
serum
level
synthetas
ifn
administr
ten
hour
ifnt
inject
synthetas
increas
pmoldl
absenc
indomethacin
pmoldl
drug
given
andreon
et
al
result
surpris
sinc
stimulatori
effect
indomethacin
serum
synthetas
seem
superior
ifnt
therefor
stimul
maintain
chronic
administr
would
worthi
test
whether
associ
inhibitor
pg
synthesi
nsaid
ifna
could
improv
antivir
respons
effect
ifng
treatment
come
year
clarif
metabol
arachidon
liver
expect
knowledg
role
deriv
liver
physiolog
improv
substanti
relev
arachidon
deriv
pathway
need
investig
sinc
compound
may
import
function
shown
kidney
excit
relationship
emerg
among
pg
lt
sever
cytokin
growth
factor
antivir
protein
need
investig
sinc
factor
modul
function
determin
ultim
evolut
acut
liver
diseas
toward
recoveri
chronic
newer
compound
therapeut
use
expect
next
year
synthet
analog
cytoprotect
pg
specif
inhibitor
antagonist
noxiou
member
arachidon
cascad
develop
present
compound
first
group
alreadi
avail
inhibitor
lt
synthesi
cysteinyllt
antagonist
although
highli
effect
experiment
model
still
possess
toxic
enough
avoid
clinic
use
